IL-31/33 Axis in Atopic Dermatitis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262010162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Julia Łacwik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Group of Microbiology and Immunology, Department of Microbiology and Immunology in Zabrze, Medical University of Silesia in Katowice…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-33, Interleukins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by impaired epidermal barrier function, immune dysregulation (e.g., Th2 polarization), genetic factors (e.g., filaggrin mutations), environmental triggers and microbial dysbiosis, leading to pruritus and eczematous lesions. In this review, we present the synergistic “IL-31/IL-33 axis.” IL-33, released by damaged keratinocytes, acts as an alarmin, initiating inflammation via ST2 receptors and promoting Th2 cytokine production (IL-4, IL-5, IL-13). This upregulates IL-31, primarily from Th2 cells, which directly activates sensory neurons to induce pruritus and impairs keratinocyte differentiation. Together, IL-31 and IL-33 exacerbate the itch–scratch feedback loop, barrier disruption, and inflammation. Elevated levels of IL-31 and IL-33 correlate with disease severity. Targeting the IL-31/IL-33 axis represents an emerging therapeutic option, e.g., nemolizumab (anti-IL-31RA) significantly reduces pruritus and AD symptoms in clinical trials. However, anti-IL-33/ST2 agents (e.g., etokimab, tozorakimab) demonstrate variable efficacy, highlighting complexity in targeting IL-33. Future research should prioritize biomarker-driven patient stratification to optimize the clinical application of these novel antibody-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Group of Microbiology and Immunology, Department of Microbiology and Immunology in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Student Research Group of Allergology and Internal Medicine, Clinical Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-556 Wrocław, Poland.
- Department of Microbiology and Immunology in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
- Clinical Department of Allergology and Internal Medicine, Wroclaw Medical University, 50-556 Wrocław, Poland.
ORCID-Profile: Julia Łacwik, Krzysztof Kraik, Maciej Tota, Łukasz Sędek, Krzysztof Gomułka
Zitieren
APA
Łacwik, J., Kraik, K., Laska, J., Tota, M., Sędek, Ł., & Gomułka, K. (2025). IL-31/33 Axis in Atopic Dermatitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262010162
Vancouver
Łacwik J, Kraik K, Laska J, Tota M, Sędek Ł, Gomułka K. IL-31/33 Axis in Atopic Dermatitis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262010162
BibTeX
@article{acwik2025,
author = {Łacwik, Julia and Kraik, Krzysztof and Laska, Julia and Tota, Maciej and Sędek, Łukasz and Gomułka, Krzysztof},
title = {IL-31/33 Axis in Atopic Dermatitis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262010162}
}
EUVIMED